Pharmaceutical Technology Europe
On 7–9 May I attended ERBI's Biopartnering Exchange in Cambridge (UK), an event that brought together national and international entrepreneurs, senior executives and industry experts of the biotechnology sector.
On 7–9 May I attended ERBI's Biopartnering Exchange in Cambridge (UK), an event that brought together national and international entrepreneurs, senior executives and industry experts of the biotechnology sector.
Bibiana Campos-Seijo
As 2008 was ERBI's 10th anniversary they really pushed the boat out: we enjoyed talks by Nobel Prize winners, Professors and one or two Sirs, and were treated to a fabulous firework display.
From where I was sitting, the meeting was hugely successful: the sessions were interesting, informative and entertaining, and the hectic biopartnering schedule saw many delegates trying to fulfil their extremely busy timetables yet maximize the quality of the time spent meeting potential clients and investors.
A very insightful session was chaired by Andy Richards, who invited four key players in the industry to discuss their experiences and reminisce about the good, the bad and the sometimes ugly days that have helped shape their careers. It was also very refreshing to hear Clive Cookson, Science Editor of the Financial Times, encouraging researchers and scientists to engage with the press and talk to journalists. Simultaneously, he called for the media to focus on the relevance of the information provided and not its entertainment value when reporting scientific developments.
And there was debate too! There seemed to be strong disagreement among the different experts with regard to funding availability (i.e., venture capitalists or VCs) and the future of the biotechnology sector. While some asserted that there are no funds and many small companies, unviable in their view, should disappear, others maintained that although a proportion of VCs appear to have vanished into thin air, there is still money, room for investment and will to aid start-up private companies. However controversial this may be, it is a sign that all parties (industry, academics, investors) are still passionately trying to steer any developments in the biotechnology sector in the right direction.
But my favourite moment of the event has to be Professor Sir Christopher Evan's presentation. Among many incisive comments, whacky slides and clever quotes, the concluding statement "I'd rather be a tiger for one day than a sheep for 100" was the icing on the cake. It is a very romantic notion indeed, but one that, I fear, remains quite invalid as a business model. It makes, however, for wonderful life ethics...
Dr Bibiana Campos-Seijo
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.